| | View this message online 
Hello manoj kumar valluru, Last week a paper was published demonstrating anti-fibrotic effects of mesenchymal stem cells derived from Wharton's Jelly. Given that Osiris's bone marrow MSC product is anticipated to attain regulatory approval sometime next year, it will be interesting to watch the expansion of universal donor stem cell uses to other fields besides GVHD. Novartis was granted a patent, #7,541,333, covering the use of FGF-2 for heart failure. It will be interesting to see whether FGF-2 will be synergistic with angiogenesis promoting stem cells. A new patent was added to the field of stem cell expansion with Pluristem being awarded #7,534,609 covering their stromal feeder-based bioreactor. In the area of expansion another patent was issued, #7,541,183, disclosing uses of wnt-family molecules for manipulation of muscle progenitor cells in vitro. Stem Cell Therapeutics was issued #7,534,765 expanding their portfolio of IP covering pharmacologically applicable molecules for modulation of the endogenous stem cell compartment. In the area of embryonic stem cells Novocell was issued another stellar patent, #7,541,186, covering methods of screening for compounds that induce endodermal differentiation. Induction of retinal cell differentiation using a 2 step process was disclosed in #7,541,186.
Media Partnerships (NEW)
| | PATENTS - WHAT'S GETTING ATTENTION? | | |
Thanks again for your help in supporting StemCellPatents.com.
Media Partnerships (NEW)
 (BETA)
------------------------------------------------------------ To unsubscribe, click here. Delivered: Tuesday June 9th, 2009 @ 14:35:10 EST | |
